Abstract
Primary open-angle glaucoma (POAG) is the second leading cause of irreversible blindness worldwide with increasing prevalence. Oral citicoline has been shown to have a role in glaucoma; however, studies regarding citicoline eye drops for glaucoma are still limited. This is a critical appraisal of the literature on the effectiveness of citicoline in improving the mean deviation (MD) of the visual field and thickness of the retinal nerve fiber layer (RNFL) in POAG. A literature search was done on 4 databases: PubMed, Cochrane, Embase, and Scopus. From the 165 studies initially identified, 3 studies were qualified for critical review. Rossetti demonstrated significant MD (p=0.02) and RNFL (p=0.04) differences after 3 years of citicoline eye drops compared to placebo. Mirachtsis showed that after citicoline administration for 3 months there was a significant difference in RNFL (p=0.029), but no significant improvement in MD (p>0.05). Parisi showed an improvement in MD after 4 months (+0.56 dB) and 6 months (+0.18 dB) of citicoline administration. Citicoline eye drops have the potential to inhibit glaucoma progression by inhibiting RNFL loss, but further research is needed on visual field improvement.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
